ISK is proud to announce a significant development in our ongoing commitment to cancer research and treatment. We have successfully developed and are now in the process of filing a patent for an enhanced form of Nerofe, our proprietary cancer treatment.

This advancement represents a major milestone in our mission to combat cancer. The enhanced form of Nerofe has shown promising potential in preclinical studies, demonstrating our continuous innovation in the field of oncology.

We remain dedicated to our mission of improving patient outcomes and will continue to share updates on the progress of this exciting development. Thank you for your continued support.